TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:02
LEAP THERAPEUTICS INC. ( LPTX ) https://www.leaptx.com
2.48USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-20.00%
LPTX
SPY
32.74%
-87.47%
LPTX
SPY
92.93%
-86.74%
LPTX
SPY
224.41%
LPTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
61.36
-8.71
0.10
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.77
40.90
1.02
-121.51
0.00
0.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.7975
-99.69
-99.49
1.75
Other Earnings and Cash Flow Stats:
LEAP THERAPEUTICS INC. ( LPTX ) Net Income TTM ($MM) is -82.70
LEAP THERAPEUTICS INC. ( LPTX ) Operating Income TTM ($MM) is -86.79
LEAP THERAPEUTICS INC. ( LPTX ) Owners' Earnings Annual ($MM) is 0.00
LEAP THERAPEUTICS INC. ( LPTX ) Current Price to Owners' Earnings ratio is 0.00
LEAP THERAPEUTICS INC. ( LPTX ) EBITDA TTM ($MM) is -83.73
LEAP THERAPEUTICS INC. ( LPTX ) EBITDA Margin is 0.00%
Capital Allocation:
LEAP THERAPEUTICS INC. ( LPTX ) has paid 0.00 dividends per share and bought back 87.673678 million shares in the past 12 months
LEAP THERAPEUTICS INC. ( LPTX ) has reduced its debt by 0.101 million USD in the last 12 months
Capital Structure:
LEAP THERAPEUTICS INC. ( LPTX ) Interest-bearing Debt ($MM) as of last quarter is 0
LEAP THERAPEUTICS INC. ( LPTX ) Annual Working Capital Investments ($MM) are -3
LEAP THERAPEUTICS INC. ( LPTX ) Book Value ($MM) as of last quarter is 60
LEAP THERAPEUTICS INC. ( LPTX ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
LEAP THERAPEUTICS INC. ( LPTX ) has 70 million in cash on hand as of last quarter
LEAP THERAPEUTICS INC. ( LPTX ) has 12 million of liabilities due within 12 months, and long term debt 0 as of last quarter
LEAP THERAPEUTICS INC. ( LPTX ) has 25 common shares outstanding as of last quarter
LEAP THERAPEUTICS INC. ( LPTX ) has 0 million USD of preferred stock value
Academic Scores:
LEAP THERAPEUTICS INC. ( LPTX ) Altman Z-Score is -7.75 as of last quarter
LEAP THERAPEUTICS INC. ( LPTX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
LEAP THERAPEUTICS INC. ( LPTX ) largest shareholder is Vanguard Group Inc owning 334713 shares at 0.83 ($MM) value
Mashiach Nissim(an insider) Bought 55000 shares of LEAP THERAPEUTICS INC. ( LPTX ) for the amount of $0.00 on 2022-01-31
2.87% of LEAP THERAPEUTICS INC. ( LPTX ) is held by insiders, and 33.04% is held by institutions
LEAP THERAPEUTICS INC. ( LPTX ) went public on 2017-01-25
Other LEAP THERAPEUTICS INC. ( LPTX ) financial metrics:
FCF:-49.85
Unlevered Free Cash Flow:-78.60
EPS:-2.14
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-91.09
Beta:1.75
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About LEAP THERAPEUTICS INC. ( LPTX ) :
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.